Arg13 of B-type natriuretic peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors

Deborah M. Dickey, Kathryn A. Barbieri, Christopher M. McGuirk, Lincoln R. Potter

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

B-type natriuretic peptide (BNP) decreases cardiac preload and hypertrophy. As such, synthetic BNP, nesiritide, was approved for the treatment of acutely decompensated heart failure. However, two problems limit its therapeutic potential. First, ensuing hypertension decreases urine output, and second, guanylyl cyclase-A (GC-A), the primary signaling receptor for BNP, is down-regulated in heart failure. Thus, alternative or chimeric natriuretic peptides maintaining the renal but lacking the vasorelaxation properties of BNP provide an alternative approach. Here, we examined the ability of single amino acid substitutions in the conserved 17-amino acid disulfide ring structure of human BNP to activate GC-A and guanylyl cyclase-B (GC-B), which is not reduced in heart failure. We hypothesized that substitution of highly conserved residues in BNP with highly conserved residues from a GC-B-specific peptide would yield BNP variants with increased and decreased potency for human GC-B and GC-A, respectively. Substitution of Leu for Arg13 (L-BNP) yielded a 5-fold more potent activator of GC-B and 7-fold less potent activator of GC-A compared with wild type. L-BNP also bound GC-A 4.5-fold less tightly than wild type. In contrast, substitution of Met for Ser21 (M-BNP) had no effect. A peptide containing both the Leu and Met substitutions behaved similarly to L-BNP. Meanwhile, wild-type and L-BNP bound the natriuretic peptide clearance receptor with similar affinities. These data indicate that Arg13 of BNP is a critical discriminator of binding to guanylyl cyclase-linked but not clearance natriuretic peptide receptors, supporting designer natriuretic peptides as an alternative to wild-type BNP for the treatment of heart failure.

Original languageEnglish (US)
Pages (from-to)431-435
Number of pages5
JournalMolecular Pharmacology
Volume78
Issue number3
DOIs
StatePublished - Sep 2010

Fingerprint

Guanylate Cyclase
Brain Natriuretic Peptide
Natriuretic Peptides
Heart Failure
Peptide Receptors
Cardiomegaly
Amino Acid Substitution
Treatment Failure

Cite this

Arg13 of B-type natriuretic peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors. / Dickey, Deborah M.; Barbieri, Kathryn A.; McGuirk, Christopher M.; Potter, Lincoln R.

In: Molecular Pharmacology, Vol. 78, No. 3, 09.2010, p. 431-435.

Research output: Contribution to journalArticle

@article{d4e3efe472e04a65ac80d9f98dbacb4d,
title = "Arg13 of B-type natriuretic peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors",
abstract = "B-type natriuretic peptide (BNP) decreases cardiac preload and hypertrophy. As such, synthetic BNP, nesiritide, was approved for the treatment of acutely decompensated heart failure. However, two problems limit its therapeutic potential. First, ensuing hypertension decreases urine output, and second, guanylyl cyclase-A (GC-A), the primary signaling receptor for BNP, is down-regulated in heart failure. Thus, alternative or chimeric natriuretic peptides maintaining the renal but lacking the vasorelaxation properties of BNP provide an alternative approach. Here, we examined the ability of single amino acid substitutions in the conserved 17-amino acid disulfide ring structure of human BNP to activate GC-A and guanylyl cyclase-B (GC-B), which is not reduced in heart failure. We hypothesized that substitution of highly conserved residues in BNP with highly conserved residues from a GC-B-specific peptide would yield BNP variants with increased and decreased potency for human GC-B and GC-A, respectively. Substitution of Leu for Arg13 (L-BNP) yielded a 5-fold more potent activator of GC-B and 7-fold less potent activator of GC-A compared with wild type. L-BNP also bound GC-A 4.5-fold less tightly than wild type. In contrast, substitution of Met for Ser21 (M-BNP) had no effect. A peptide containing both the Leu and Met substitutions behaved similarly to L-BNP. Meanwhile, wild-type and L-BNP bound the natriuretic peptide clearance receptor with similar affinities. These data indicate that Arg13 of BNP is a critical discriminator of binding to guanylyl cyclase-linked but not clearance natriuretic peptide receptors, supporting designer natriuretic peptides as an alternative to wild-type BNP for the treatment of heart failure.",
author = "Dickey, {Deborah M.} and Barbieri, {Kathryn A.} and McGuirk, {Christopher M.} and Potter, {Lincoln R.}",
year = "2010",
month = "9",
doi = "10.1124/mol.110.066084",
language = "English (US)",
volume = "78",
pages = "431--435",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Arg13 of B-type natriuretic peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors

AU - Dickey, Deborah M.

AU - Barbieri, Kathryn A.

AU - McGuirk, Christopher M.

AU - Potter, Lincoln R.

PY - 2010/9

Y1 - 2010/9

N2 - B-type natriuretic peptide (BNP) decreases cardiac preload and hypertrophy. As such, synthetic BNP, nesiritide, was approved for the treatment of acutely decompensated heart failure. However, two problems limit its therapeutic potential. First, ensuing hypertension decreases urine output, and second, guanylyl cyclase-A (GC-A), the primary signaling receptor for BNP, is down-regulated in heart failure. Thus, alternative or chimeric natriuretic peptides maintaining the renal but lacking the vasorelaxation properties of BNP provide an alternative approach. Here, we examined the ability of single amino acid substitutions in the conserved 17-amino acid disulfide ring structure of human BNP to activate GC-A and guanylyl cyclase-B (GC-B), which is not reduced in heart failure. We hypothesized that substitution of highly conserved residues in BNP with highly conserved residues from a GC-B-specific peptide would yield BNP variants with increased and decreased potency for human GC-B and GC-A, respectively. Substitution of Leu for Arg13 (L-BNP) yielded a 5-fold more potent activator of GC-B and 7-fold less potent activator of GC-A compared with wild type. L-BNP also bound GC-A 4.5-fold less tightly than wild type. In contrast, substitution of Met for Ser21 (M-BNP) had no effect. A peptide containing both the Leu and Met substitutions behaved similarly to L-BNP. Meanwhile, wild-type and L-BNP bound the natriuretic peptide clearance receptor with similar affinities. These data indicate that Arg13 of BNP is a critical discriminator of binding to guanylyl cyclase-linked but not clearance natriuretic peptide receptors, supporting designer natriuretic peptides as an alternative to wild-type BNP for the treatment of heart failure.

AB - B-type natriuretic peptide (BNP) decreases cardiac preload and hypertrophy. As such, synthetic BNP, nesiritide, was approved for the treatment of acutely decompensated heart failure. However, two problems limit its therapeutic potential. First, ensuing hypertension decreases urine output, and second, guanylyl cyclase-A (GC-A), the primary signaling receptor for BNP, is down-regulated in heart failure. Thus, alternative or chimeric natriuretic peptides maintaining the renal but lacking the vasorelaxation properties of BNP provide an alternative approach. Here, we examined the ability of single amino acid substitutions in the conserved 17-amino acid disulfide ring structure of human BNP to activate GC-A and guanylyl cyclase-B (GC-B), which is not reduced in heart failure. We hypothesized that substitution of highly conserved residues in BNP with highly conserved residues from a GC-B-specific peptide would yield BNP variants with increased and decreased potency for human GC-B and GC-A, respectively. Substitution of Leu for Arg13 (L-BNP) yielded a 5-fold more potent activator of GC-B and 7-fold less potent activator of GC-A compared with wild type. L-BNP also bound GC-A 4.5-fold less tightly than wild type. In contrast, substitution of Met for Ser21 (M-BNP) had no effect. A peptide containing both the Leu and Met substitutions behaved similarly to L-BNP. Meanwhile, wild-type and L-BNP bound the natriuretic peptide clearance receptor with similar affinities. These data indicate that Arg13 of BNP is a critical discriminator of binding to guanylyl cyclase-linked but not clearance natriuretic peptide receptors, supporting designer natriuretic peptides as an alternative to wild-type BNP for the treatment of heart failure.

UR - http://www.scopus.com/inward/record.url?scp=77956245721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956245721&partnerID=8YFLogxK

U2 - 10.1124/mol.110.066084

DO - 10.1124/mol.110.066084

M3 - Article

C2 - 20530652

AN - SCOPUS:77956245721

VL - 78

SP - 431

EP - 435

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 3

ER -